Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

Lapatinib, an oral, reversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, has proven antitumor activity in HER2-positive metastatic breast cancer (MBC). Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is indicated for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yardley, Denise A., Hart, Lowell, Bosserman, Linda, Salleh, Mansoor N., Waterhouse, David M., Hagan, Maura K., Richards, Paul, DeSilvio, Michelle L., Mahoney, Janine M., Nagarwala, Yasir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539071/
https://www.ncbi.nlm.nih.gov/pubmed/23224144
http://dx.doi.org/10.1007/s10549-012-2341-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539071/
https://www.ncbi.nlm.nih.gov/pubmed/23224144
http://dx.doi.org/10.1007/s10549-012-2341-9

Ejemplares similares